AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors
07 December 2021 - 12:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical
stage biotechnology company focused on the development and
commercialization of adeno-associated virus (AAV)-based gene
therapies for the treatment of rare and debilitating diseases with
an initial focus on inherited retinal diseases (IRDs), today
announced the appointment of James Robinson, President and Chief
Executive Officer (CEO) of Urovant Sciences, to its Board of
Directors.
“We are honored to have Jim join our Board of Directors, where
his exemplary track record of execution as an executive at leading
biotech and pharma companies will be invaluable to AGTC as we seek
to deliver on the clinical and commercial promise of our robust
pipeline including our late stage XLRP and ACHM programs,” said Sue
Washer, President and CEO of AGTC. “Jim’s appointment, along with
the recent appointments to our executive leadership team, usher in
a new, exciting chapter for AGTC as we close a successful 2021 and
focus on our many opportunities for success in 2022 including key
milestones in XLRP and ACHM.”
Mr. Robinson is an expert in building, deploying and leading
successful organizations from their earliest stages of development
through their emergence as commercial enterprises, and has
successfully led multiple global businesses, operations and
commercial ventures over the past 28 years. A proven industry
leader, Mr. Robinson served as a member of the Urovant Board of
Directors prior to being appointed Urovant’s CEO in 2020. Prior to
his role at Urovant, Mr. Robinson held the position of President
and Chief Operating Officer at Paragon Biosciences. He came to this
role after serving as the President and Chief Operating Officer of
Alkermes, where he was responsible for global commercial
operations, new product planning, corporate planning,
manufacturing, quality, human resources and business
development.
“I am excited to join AGTC’s Board of Directors at a time when
the organization has already made impressive progress developing
its pipeline of gene therapies, particularly in ophthalmology,”
said Mr. Robinson. “I look forward to contributing my operational
and commercial experience and working closely with Sue and the
executive leadership team.”
Prior to Alkermes, Mr. Robinson spent more than a decade at
Astellas U.S. – most recently as President, Americas Operations and
previously as President of Astellas Pharma US, where he was
responsible for leading the U.S. commercial organization. Prior to
Astellas, Mr. Robinson spent thirteen years at Schering-Plough
Pharmaceuticals where his last role was Vice President, Hepatitis
Sales and Managed Care.
Mr. Robinson serves on the Board of Directors for Urovant
Sciences and is an advisor to BridgeBio Pharma. Mr. Robinson
previously served on the Board of Directors of the Pharmaceutical
Research and Manufacturers of America (PhRMA) and served as
Chairman of PhRMA’s State Committee. He is a founding member of
MATTER, the Commercial Club of Chicago and member of the Chicago
Chapter of the Young Presidents Organization. Mr. Robinson received
a Bachelor of Science degree from DePaul University.
About AGTCAGTC is a clinical-stage
biotechnology company developing genetic therapies for people with
rare and debilitating ophthalmic, otologic and central nervous
system (CNS) diseases. AGTC is a leader in designing and
constructing all critical gene therapy elements and bringing them
together to develop customized therapies with the potential to
address real patient needs. AGTC’s most advanced clinical programs
leverage its best-in-class technology platform to potentially
improve vision for patients with an inherited retinal disease. AGTC
has active clinical trials in X-linked retinitis pigmentosa (XLRP)
and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical
programs build on the Company’s industry leading AAV manufacturing
technology and scientific expertise. AGTC is advancing multiple
important pipeline candidates to address substantial unmet clinical
need in optogenetics, otology and CNS disorders, including entering
into strategic collaborations with companies including Otonomy,
Inc., a biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology, and Bionic Sight, LLC, an
innovator in the emerging field of optogenetics and retinal coding.
For more information, please visit www.agtc.com/.
Forward-Looking Statements This release
contains forward-looking statements that reflect AGTC's plans,
estimates, assumptions and beliefs, including statements about the
potential of the Company’s AGTC-501 product candidate, the ongoing
late-stage development programs in XLRP and ACHM and the potential
for the Company’s gene therapy platform. Forward-looking statements
include information concerning preclinical and clinical product
development and regulatory progress, potential growth
opportunities, and potential market opportunities. Forward-looking
statements include all statements that are not historical facts and
can be identified by terms such as "anticipates," "believes,"
"could," "seeks," "estimates," "expects," "intends," "may,"
"plans," "potential," "predicts," "projects," "should," "will,"
"would" or similar expressions and the negatives of those terms.
Actual results could differ materially from those discussed in the
forward-looking statements, due to a number of important
factors. Risks and uncertainties that may cause actual results to
differ materially include, among others: gene therapy is still
novel with only a few approved treatments so far; AGTC cannot
predict when or if it will obtain regulatory approval to
commercialize a product candidate or receive reasonable
reimbursement; uncertainty inherent in clinical trials and the
regulatory review process, including that interim results are not
necessarily indicative of final results; risks and uncertainties
associated with drug development and commercialization; the direct
and indirect impacts of the ongoing COVID-19 pandemic on our
business, results of operations, and financial condition; factors
that could cause actual results to differ materially from those
described in the forward-looking statements are set forth under the
heading "Risk Factors" in our most recent annual report on Form
10-K and subsequent periodic reports filed with the SEC. Given
these uncertainties, you should not place undue reliance on these
forward-looking statements. Also, forward-looking statements
represent management's plans, estimates, assumptions and beliefs
only as of the date of this release. Except as required by law, we
assume no obligation to update these forward-looking statements
publicly or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future.
PR Contact:
Kerry Sinclair
Spectrum Science Communications
ksinclair@spectrumscience.com
Corporate Contact:
Jon Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024